Menu
Scroll to Top
Locations
San Francisco, CA, USA
industry
Biotechnology · DeepTech · Health
Size
1 - 10 employees
Stage
Seed
founded in
2023
VIAN Therapeutics is an early-stage biotechnology company focused on transforming retinal disease treatment. With a first-in-class, non-invasive eyedrop as its lead product, VIAN aims to replace invasive injections for conditions like age-related macular degeneration (AMD) and diabetic macular edema (DME). Backed by strong preclinical data and ongoing clinical testing, VIAN is positioned to address significant unmet medical needs and disrupt the $15 billion retinal disease market.
Something looks off?